Pharmacological modulation of IGF serum concentrations as a therapeutic approach to control the growth of malignant breast tumors

Drugs of Today

Volumn 39, Issue 2, 2003, Pages 115-125

  Singer, Christian F ^a   Hudelist, Gernot ^a   Schreiber, Martin ^a   Kubista, Ernst ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; DROLOXIFENE; ESTROGEN; FENRETINIDE; FULVESTRANT; LETROZOLE; OCTREOTIDE; QUINAGOLIDE; RETINOID; RETINOL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEOCALCITOL; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; VITAMIN D; VITAMIN D DERIVATIVE; VOROZOLE;

BLADDER CANCER; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; FEMALE; HUMAN; MALE; METASTASIS; NONHUMAN; PHASE 3 CLINICAL TRIAL; RAT; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MIDDLE AGED; PROGESTINS; RETINOIDS; TAMOXIFEN;

EID: 0037321445     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.2.740211     Document Type: Review

References (79)

1. Hwa, V., Oh, Y., Rosenfeld, R.G. The insulinlike growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999, 20: 761-87.
2. Hankinson, S.E. Overview of breast cancer population studies. Growth Horm IGF Res 2000, 10 (Suppl. A): S22-3.
3. Hankinson, S.E., Willett, W.C., Colditz, G.A., Hunter, D.J., Michaud, D.S., Deroo, B., Rosner, B., Speizer, F.E., Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351: 1393-6.
4. Li, B.D., Khosravi, M.J., Berkel, H.J., Diamandi, A., Dayton, M.A., Smith, M., Yu, H. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001, 91: 736-9.
5. Peyrat, J.P., Bonneterre, J., Hecquet, B., Vennin, P., Louchez, M.M. Fournier, C., Levebvre, J., Demaille, A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer Eur J Cancer 1993, 29: 492-7.
6. Rocha, R.L., Hilsenbeck, S.G., Jackson, J.G., van den Berg, C.L., Wenig, C.N., Lee, A.V., Yee, D. Insulin-like growth factor binding protein-3 and insulin receptor substrate in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997, 3: 103-9.
7. Bruning, P.F., Van Doorn, J., Bonfrer, J.M., Van Noord, P.A., Korse, C.M., Linders, T.C., Hart, A.A. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer 1995, 62: 266-70,
8. Yang, X.F., Beamer, W., Huynh, H., Pollak, M. Reduced growth of human breast cancer xenografts in hosts homocygous for the 'lit' mutation. Cancer Res 1996, 56: 1509-11.
9. Cullen, K.J., Lippman, M.E., Chow, D., Hill, S., Rosen, N., Zwiebel, J.A. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol 1992, 6: 91-100.
10. Holdaway, I.M., Lethaby, A.E., Mason, B.H., Singh, V., Harman, J.E., MacCormick, M., Civil, I.D. Effect of breast surgery on serum levels of insulin-like growth factors (IGF-I, IGF-II, and IGF binding protein-3) in women with benign and malignant breast lesions. Ann Surg Oncol 2001, 8: 25-31.
11. Singer, C.F., Mogg, M., Koestler, W., Marton, E., Pacher, E., Kubista, E., Schreiber, M. IGF-1 and IGF-2 serum concentrations in patients with benign and malignant breast cancer: Free IGF-2 is correlated with breast tumor size. Eur J Cancer 2002, 38 (Suppl. 3): S54.
12. Yu, H., Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000, 92: 1472-89.
13. Arteaga, C.L., Osborne, C.K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor Cancer Res 1989, 49: 6237-41.
14. Osborne, C.K., Coronado, E.B., Kitten, L.J., Arteaga, C.I., Fuqua, S.A., Ramasharma, K., Marshall, M., Li, C.H. Insulin-like growth factor-II (IGF-II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor Mol Endocrinol 1989, 3: 1701-9.
15. Zhang, X., Yee, D. Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2000, 2: 170-5.
16. McKinnon, T., Chakraborty, C., Gleeson, L.M., Chidiac, P., Lala, P.K. Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK. J Clin Endocrinol Metab 2001, 86: 3665-74.
17. Minniti, C.P., Kohn, E.C., Grubb, J.H., Sly, W.S., Oh, Y., Muller, H.L., Rosenfeld, R.G., Helman, L.J. The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells. J Biol Chem 1992, 267: 9000-4.
18. Dahms, N.M., Lobel, P., Kornfeld, S. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem 1989, 264: 12115-8.
19. Ellis, M.J., Leav, B.A., Yang, Z., Rasmussen, A., Pearce, A., Zweibel, J.A., Lippman, M.E., Cullen, K.J. Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells. Mol Endocrinol 1996, 10: 286-97.
20. Osipo, C., Dorman, S., Frankfater, A. Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors. Exp Cell Res 2001, 264: 388-96.
21. Singer, C.F., Kubista, E., Garmroudi, F., Cullen, K.J. Local feedback mechanisms in human breast cancer. Breast Cancer Res Treat 2000, 63: 95-104.
22. Cullen, K.J., Smith, H.S., Hill, S., Rosen, N., Lippman, M.E. Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 1991, 51: 4978-85.
23. Quinn, K.A., Treston, A.M., Unsworth, E.J., Miller, M.J., Vos, M., Grimley, C., Battey, J., Mulshine, J.L., Cuttitta, F. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996, 271: 11477-83.
24. Singer, C., Rasmussen, A., Smith, H.S., Lippman, M.E., Lynch, H.T., Cullen, K.J. Malignant breast epithelium selects for insulinlike growth factor II expression in breast stroma: Evidence for paracrine function. Cancer Res 1995, 55: 2448-54.
25. Thorsen, T., Lahooti, H., Rasmussen, M., Aakvaag, A. Oestradiol treatment increases the sensitivity of MCF-7 cells for the growth stimulatory effect of IGF-I. J Steroid Biochem Mol Biol 1992, 41: 537-40.
26. Hamelers, I.H., van Schaik, R.F., van Teeffelen, H.A., Sussenbach, J.S., Steenbergh, P.H. Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF7S breast tumor cells. Exp Cell Res 2002, 273: 107-17.
27. Lai, A., Sarcevic, B., Prall, O.W., Sutherland, R.L. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). J Biol Chem 2001,276: 25823-33.
28. Pratt, S.E., Pollak, M.N. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 1994, 198: 292-7.
29. Figueroa, J.A., Sharma, J., Jackson, J.G., McDermott, M.J., Hilsenbeck, S.G., Yee, D. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-1, serum, and estrogendependent growth of MCF-7 human breast cancer cells. J Cell Physiol 1993, 157: 229-36.
30. Westley, B.R., Clayton, S.J., Daws, M.R., Molloy, C.A., May, F.E. Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation. Biochem Soc Symp 1998, 63: 35-44.
31. Katzenellenbogen, B.S., Norman, M.J. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology 1990, 126: 891-8.
32. Cho, H., Aronica, S.M., Katzenellenbogen, B.S. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: A comparison of the effects of cyclic adenosine 3′,5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology 1994, 134: 658-64.
33. Veldhuis, J.D., Iranmanesh, A. Physiological regulation of the human growth hormone (GH)insulin-like growth factor type I (IGF-I) axis: Predominant impact of age, obesity, gonadal function, and sleep. Sleep 1996, 19 (Suppl. 10): S221-4.
34. Hintz, R.L. Current and potential therapeutic uses of growth hormone and insulin-like growth factor I. Endocrinol Metab Clin North Am 1996, 25: 759-73.
35. Simpson, H.L., Umpleby, A.M., Russell-Jones, D.L. Insulin-like growth factor-I and diabetes. A review. Growth Horm IGF Res 1998, 8: 83-95.
36. Thierry van Dessel, H.J., Chandrasekher, Y., Yap, O.W., Lee, P.D., Hintz, R.L., Faessen, G.H., Braat, D.D., Fauser, B.C., Giudice, L.C. Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle. J Clin Endocrinol Metab 1996, 81: 1224-31.
37. Juul, A., Scheike, T., Pedersen, A.T., Main, K.M., Andersson, A.M., Pedersen, L.M., Skakkebaek, N.E. Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factorbinding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Hum Reprod 1997, 12: 2123-8.
38. Wang, H.S., Lee, J.D., Soong, Y.K. Serum levels of insulin-like growth factor I and insulin-like growth factor-binding protein-1 and -3 in women with regular menstrual cycles. Fertil Steril 1995, 63: 1204-9.
39. Ho, K.K., O'Sullivan, A.J., Weissberger, A.J., Kelly, J.J. Sex steroid regulation of growth hormone secretion and action. Horm Res 1996, 45: 67-73.
40. Kaaks, R., Lukanova, A. Energy balance and cancer: The role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001, 60: 91-106.
41. Clarke, R.B., Howell, A., Anderson, E. Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: Analysis of the relationship between estrogeninduced proliferation and progesterone receptor expression. Breast Cancer Res Treat 1997, 45: 121-33.
42. Rosen, C.J., Glowacki, J., Craig, W. Sex steroids, the insulin-like growth factor regulatory system, and aging: Implications for the management of older postmenopausal women. J Nutr Health Aging 1998, 2: 39-44.
43. Helle, S.I., Lundgren, S., Geisler, S., Ekse, D., Holly, J.M., Lonning, P.E. Effects of treatment with megestrol acetate on the insulin-like growth factor system: Time and dose dependency. Eur J Cancer 1999, 35: 1070-5.
44. Frost, V.J., Helle, S.I., Lonning, P.E., van der Stappen, J.W., Holly, J.M. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 1996, 81: 2216-21.
45. Helle, S.I., Jonat, W., Giurescu, M., Ekse, D,. Holly, J.M., Lonning, P.E. Influence of treatment with onapristone on the IGF-system in breast cancer patients. J Steroid Biochem Mol Biol 1998, 66: 159-63.
46. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998, 351: 1451-67.
47. Mandala, M., Moro, C., Ferretti, G., Calabro, M.G., Nole, F., Rocca, A., Munzone, E., Castro, A., Curigliano, G. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. Anticancer Res 2001, 21: 585-8.
48. Bonanni, B., Johansson, H., Gandini, S., Guerrieri-Gonzaga, A., Torrisi, R., Sandri, M.T., Cazzaniga, M., Mora, S., Robertson, C., Lien, E.A., Decensi, A. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res Treat 2001, 69: 21-7.
49. Torrisi, R., Baglietto, L., Johansson, H., Veronesi, G., Bonanni, B., Guerrieri-Gonzaga, A., Ballardini, B., Decensi, A. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 2001, 85: 1838-41.
50. Andersson, B., Johannsson, G., Holm, G., Bengtsson, B.A., Sashegyi, A., Pavo, I., Mason, T., Anderson, P.W. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: A randomized clinical trial. J Clin Endocrinol Metab 2002, 87: 1220-8.
51. Harper-Wynne, C.L., Sacks, N.P., Shenton, K., MacNeill, F.A., Sauven, P., Laidlaw, I.J., Rayter, Z., Miall, S., Howes, A., Salter, J., Hills, M.J., Lowe, F.M., A'Hern, R., Nasiri, N., Doody, D., Iqbal, J., Dowsett, M. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002, 20: 1026-35.
52. Helle, S.I., Anker, G.B., Tally, M., Hall, K., Lonning, P.E. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol 1996, 57: 167-71.
53. Chan, T.W., Pollak, M., Huynh, H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clin Cancer Res 2001, 7: 2545-54.
54. Lamberts, S.W., Krenning, E.P., Klijn, J.G., Reubi, J.C. The clinical use of somatostatin analogues in the treatment of cancer. Baillieres Clin Endocrinol Metab 1990, 4: 29-49.
55. Muller, J., Juul, A., Andersson, A.M., Sehested, A., Skakkebaek, N.E. Hormonal changes during GnRH analogue therapy in children with central precocious puberty. J Pediatr Endocrinol Metab 2000, 13 (Suppl. 1): 739-46.
56. Dolan, J.T., Miltenburg, D.M., Granchi, T.S., Miller, C.C. 3rd, Brunicardi, F.C. Treatment of metastatic breast cancer with somatostatin analogues - A meta-analysis. Ann Surg Oncol 2001, 8: 227-33.
57. Ingle, J.N., Suman, V.J., Kardinal, C.G., Krook, J.E., Mailliard, J.A., Veeder, M.H., Loprinzi, C.L., Dalton, R.J., Hartmann, L.C., Conover, C.A., Pollak, M.N. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999, 85: 1284-92.
58. Canobbio, L., Cannata, D., Miglietta, L., Boccardo, F. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: Clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res 1995, 15: 2687-90.
59. Bontenbal, M., Foekens, J.A., Lamberts, S.W., de Jong, F.H., van Putten, W.L., Braun, H.J., Burghouts, J.T., van der Linden, G.H., Klijn, J.G. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: A randomized study with long-term follow-up. Br J Cancer 1998, 77: 115-22.
60. Ferrari, L., Martinetti, A., Zilembo, N., Pozzi, P., Buzzoni, R., La Torre, I., Gattinoni, L., Catena, L., Vitali, M., Celio, L., Seregni, E., Bombardieri, E., Bajetta, E. Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. J Steroid Biochem Mol Biol 2002, 80: 411-8.
61. Bajetta, E., Ferrari, L., Celio, L., Mariani, L., Miceli, R., Di Leo, A., Zilembo, N., Buzzoni, R., Spagnoli, I., Martinetti, A., Bichisao, E., Seregni, E. The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. J Steroid Biochem Mol Biol 1997, 63: 261-7.
62. Lien, E.A., Johannessen, D.C., Aakvaag, A., Lonning, P.E. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol 1992, 41: 541-3.
63. Harper-Wynne, C.L., Sacks, N.P., Shenton, K., MacNeill, F.A., Sauven, P., Laidlaw, I.J., Rayter, Z., Miall, S., Howes, A., Salter, J., Hills, M.J., Lowe, F.M., A'Hern, R., Nasiri, N., Doody, D., Iqbal, J., Dowsett, M. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002, 20: 1026-35.
64. Kasid, A., Lippman, M.E. Estrogen and oncogene mediated growth regulation of human breast cancer cells. J Steroid Biochem 1987, 27: 465-70.
65. Goss, P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control 2002, 9 (Suppl. 2): 2-8.
66. Brueggemeier, R.W. Aromatase inhibitors in breast cancer therapy. Expert Rev Anticancer Ther 2002, 2: 181-91.
67. Moon, R.C., Pritchard, J.F., Mehta, R.G., Nomides, C.T., Thomas, C.F., Dinger, N.M. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis 1989, 10: 1645-9.
68. Decensi, A., Johansson, H., Miceli, R., Mariani, L., Camerini, T., Cavadini, E., Di Mauro, M.G., Barreca, A., Gonzaga, A.G., Diani, S., Sandri, M.T., De Palo, G., Formelli, F. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer. Cancer Epidemiol Biomarkers Prev 2001, 10: 1047-53.
69. Favoni, R.E., de Cupis, A., Bruno, S., Yee, D., Ferrera, A., Pirani, P., Costa, A., Decensi, A. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br J Cancer 1998, 77: 2138-47.
70. Torrisi, R., Decensi, A., Formelli, F., Camerini, T., De Palo, G. Chemoprevention of breast cancer with fenretinide. Drugs 2001, 61: 909-18.
71. Torrisi, R., Mezzetti, M., Johansson, H., Barreca, A., Pigatto, F., Robertson, C., Decensi, A. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer 2000, 87: 601-5.
72. Colston, K.W., Hansen, C.M. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002, 9: 45-59.
73. Pirianov, G., Colston, K.W. Interaction of vitamin D analogs with signaling pathways leading to active cell death in breast cancer cells. Steroids 2001, 66: 309-18.
74. Colston, K.W., Perks, C.M., Xie, S.P., Holly, J.M. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 1998, 20: 157-62.
75. Xie, S.P., Pirianov, G., Colston, K.W. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer 1999, 35: 1717-23.
76. Xie, S.P., James, S.Y., Colston, K.W. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol 1997, 154: 495-504.
77. Rozen, F., Yang, X.F., Huynh, H., Pollak, M. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J Natl Cancer Inst 1997, 89: 652-6.
78. Rozen, F., Pollak, M. Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 1999, 5: 589-94.
79. Oh, Y.S., Kim, E.J., Schaffer, B.S., Kang, Y.H., Binderup, L., MacDonald, R.G., Park, J.H. Synthetic low-calcaemic vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol 2001, 183: 141-9.